Author Interviews, Cancer Research, Exercise - Fitness, Hematology / 16.12.2024

MedicalResearch.com Interview with: Janine Joseph, MS, MBA Senior Research Specialist Cancer Prevention & Control Roswell Park Comprehensive Cancer Center Buffalo, NY MedicalResearch.com: What is the background for this study? Response: Due to improvements in treatments, patients with multiple myeloma (MM) are experiencing longer lifespans and seeking ways to enhance their quality-of-life.  Fatigue, pain and negative psychological states such as anxiety and depression are common in cancer patients, including patients with MM.  Pain is particularly relevant, as MM can cause painful osteolytic (bone) lesions. The trials we discussed at ASH were aimed at evaluating the effect of exercise, specifically supervised resistance training and unsupervised walking exercise, on these and other states, including physical function and immune profile. (more…)
Author Interviews, Cancer Research, JAMA / 06.09.2022

MedicalResearch.com Interview with: Samir Parekh, MBBS Hematology-Oncology, Cancer Director of Translational Research in Myeloma and Co-leader of the Cancer Clinical Investigation program The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? What are the main findings? Response: Clinical outcomes for myeloma patients patients have improved significantly over the past decade with the introduction and success of newer immunomodulatory treatments such as CART cell therapy and bispecific antibodies. Strategies are needed to determine the best treatment options for patients relapsing or unresponsive to initial courses of these types of therapies. We analyzed the outcomes of patients relapsing after bispecific antibody therapy for myeloma. Our data shows that sequencing of bispecific antibodies or CART after initial bispecific failure can effectively salvage patients and lead to excellent outcomes in myeloma. This provides the foundation for future studies combining this new class of immunotherapy with CART or additional bispecific antibodies to improve outcomes in myeloma. (more…)